Belite Bio's drug for genetic eye disease meets main goal in late-stage trial

Reuters
Dec 01
<a href="https://laohu8.com/S/BLTE">Belite Bio</a>'s drug for genetic eye disease meets main goal in late-stage trial

Dec 1 (Reuters) - Belite Bio BLTE.O said on Monday that its experimental drug for a rare genetic eye disease met the main goal in a late-stage study.

(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Vijay Kishore)

((Padmanabhan.Ananthan@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10